Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kezar Life Sciences (KZR) EBIT (2021 - 2025)

Historic EBIT for Kezar Life Sciences (KZR) over the last 5 years, with Q2 2025 value amounting to -$14.6 million.

  • Kezar Life Sciences' EBIT rose 3756.58% to -$14.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$75.7 million, marking a year-over-year increase of 2935.45%. This contributed to the annual value of -$90.6 million for FY2024, which is 1868.45% up from last year.
  • As of Q2 2025, Kezar Life Sciences' EBIT stood at -$14.6 million, which was up 3756.58% from -$17.6 million recorded in Q1 2025.
  • Kezar Life Sciences' 5-year EBIT high stood at -$13.0 million for Q2 2021, and its period low was -$34.6 million during Q4 2023.
  • For the 5-year period, Kezar Life Sciences' EBIT averaged around -$20.4 million, with its median value being -$20.0 million (2022).
  • In the last 5 years, Kezar Life Sciences' EBIT plummeted by 7265.15% in 2023 and then soared by 3765.94% in 2024.
  • Kezar Life Sciences' EBIT (Quarter) stood at -$14.1 million in 2021, then tumbled by 42.05% to -$20.0 million in 2022, then plummeted by 72.65% to -$34.6 million in 2023, then soared by 37.66% to -$21.6 million in 2024, then skyrocketed by 32.3% to -$14.6 million in 2025.
  • Its EBIT stands at -$14.6 million for Q2 2025, versus -$17.6 million for Q1 2025 and -$21.6 million for Q4 2024.